KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal... Read more.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent... Read more.
Chimera Increases First Quarter 2026 Common Stock Dividend to $0.45 and Declares First Quarter 2026 Preferred Stock Dividends
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.45 PER SHARE OF COMMON STOCK BOARD EXPECTS CHIMERA TO MAINTAIN A QUARTERLY DIVIDEND OF $0.45 PER COMMON SHARE FOR... Read more.
Partners Capital Closes $1+ Billion Merlin IV Co-Investment Fund, Strengthening Global Platform
BOSTON & LONDON–(BUSINESS WIRE)–Partners Capital Investment Group (“Partners Capital”), a leading global investment firm with over $70 billion... Read more.
SharkNinja Reports Fourth Quarter and Full Year 2025 Results
Provides Fiscal Year 2026 Outlook Announces Inaugural $750 Million Share Repurchase Authorization NEEDHAM, Mass.–(BUSINESS WIRE)–SharkNinja, Inc. (“SharkNinja”... Read more.
Sandy Voss Joins Life Science Connect as Senior Vice President of Live Events
PITTSBURGH–(BUSINESS WIRE)–Life Science Connect (LSC), a network of life science go-to-work solutions, today announced the appointment of Sandy Voss... Read more.
NiSource Announces Full-Year 2025 Results
Achieved 2025 non-GAAP adjusted EPS above guidance range Exceeded 2025 non-GAAP FFO/Debt guidance range Reaffirming 2026 non-GAAP consolidated adjusted EPS guidance... Read more.
Wabtec Delivers Strong Fourth Quarter 2025 Results; Announces 2026 Full-Year Guidance
Multi-year backlog reaches another record at $27 Billion, up 23% versus prior year Full Year GAAP Earnings per Share of $6.83, up 13% & Adjusted Earnings per... Read more.
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeOne–BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report... Read more.
PitchBook Introduces the First Daily Valuation Model for VC-Backed Companies
Powered by machine learning, PitchBook Valuation Estimates delivers an independent valuation framework for private companies SEATTLE–(BUSINESS WIRE)–PitchBook,... Read more.